Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Latanoprost, minoxidil, and betamethasone for limited alopecia areata
IRCT20211109053013N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Dec 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of latanoprost, minoxidil and betamethasone in alopecia areata (6 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Severity of alopecia by SALT score and Patient satisfaction with treatment. Started Dec 2021; status: completed.
02
Drugs
latanoprostminoxidilbetamethasone
03
Conditions
alopecia areata
Beyond the preview
Go deeper on IRCT20211109053013N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211109053013N1.